Molecular Diagnostics: Major World Markets

Abstract

Molecular diagnostics (also known as nucleic acid testing) has emerged as a field that promises to renew technological progress in the clinical laboratory and to vastly improve patient care. Although it has been a slower than anticipated adoption in the clinical laboratory setting, molecular diagnostics has begun to overcome the impediments of incomplete genetic knowledge, the development of new technology platforms, and the communication of their use and efficacy to lab personnel and clinicians alike.

A series of technologies developed over the years to address the challenges of molecular diagnostics include eight major areas: amplification technologies (gene and signal), blotting technologies, electrophoretic technologies, microarray technologies, probe technologies, restriction fragment-length polymorphism (RFLP) analysis, RNA inhibition analysis, and single nucleotide polymorphism (SNP) analysis and software. Further, there is significant overlap among these technologies in that they can support one another. These developments have set the stage for excellent growth potential in this marketplace.

Kalorama' s Molecular Diagnostics: Major World Markets completely re-examines the molecular diagnostics market and expands its well respected previous editions. The report features:

• Market Potential in terms of number of tests (testing volume) and market size (dollar volume) through 2016 for strategic planning and new product consideration.
• 110 Tables and Figures detailing the data and trends in each country and segment/subsegment for quick reference and encorporation into proposals, internal memos and business plans.
• In-depth profiles (averaging 5 pages each) of top 10 competitors, detailing product offerings, recent announcements and acquisitions, and strategies..
• Discussion of the major technologies, including developments, products, benefits and drawbacks of:
  • amplification technologies (gene and signal)
  • blotting technologies
  • electrophoresis technologies
  • microarray technologies
  • probe technologies
  • restriction fragment-length polymorphism (RFLP)
  • RNA inhibition analysis
  • single nucleotide polymorphism (SNP) analysis
• 14 High level conclusions about the marketplace, each with a discussion of its strategic implication to assist executives in understanding how the trends and data affect their business decisions.
• Two tables (over 70 pages in length) list both marketed products and key "home-brew" molecular tests currently in use.

(The U.S. Market for Molecular Diagnostics) to include all seven of the major world healthcare markets, including:

• France
• Germany
• Italy
• Japan
• Spain
• The United Kingdom
• The United States